Prof. G. Guillain. Neurologes neurolog'iques. 3-я серия. Стр. 453, рис. 119 Masson etemp-edema. Ц. фр. 70.

In this volume, prof. Guillain collected the last works of his supervisor. Salpetriera clinics; he divided them into 7 sections: cerebral tumors, pathology of the brain, pathology of the legs of the pons, the medulla oblongata, the cerebellum, pathology of the spinal cord, pathology of the cranial and spinal nerves, muscle atrophy and other, and then a chapter on the history of neurology, dedicated to the works of the famous Boulogne neuropathologist Duchenne.

Indirect Evidence of Increased Cerebral Plasticity of Musicians with Malignant Cerebral Tumors; Longer Overall Survival Status according to Nonmusicians

Background There are some reported musicians with cerebral tumors, but no comparative study of the survival status of musician and nonmusician patients with malignant cerebral tumors was made. This subject was investigated. Material and methods Musician people list with cerebral tumors was searched from the English Wikipedia (https://en.wikipedia.org/wiki/List_of_people_with_brain_tumors). Their survival status, ages, and gender were statistically compared with 30 nonmusician patients with cerebral malign tumors. Results 66 (Group 1 or Musician Group; MG) musicians with malignant tumors list were found from Wikipedia. Survival times of only 47 musicians could be reached from Wikipedia. The mean Survival of this group is 20.06 months, however, it was 13.10 months non-musician group, and the difference of survival was statistically significant (p < 0.05), however, ages and gender were not. Conclusion There is an interaction between music and brain anatomic structures. Our study showed that the survival status of musicians and non-musician with malign cerebral tumors is not the same. This result may be dependent on the altered musician's brain or neuronal plasticity, and the response of the musician's brain's to malign tumor. More studies are needed.

Duration and Mortality Characteristics of Patients with Cerebral Tumors Treated in the Intensive Care Unit of Sanglah General Hospital from January to December 2017

BACKGROUND: The incidence and survival rates of cerebral tumor patients are increasing, along with advances in medical technology. Severe complications, such as multiorgan failure in patients, cause the need for intensive care to improve. The effectiveness of intensive care in tumor patients is still controversial, considering that patients included in low and vulnerable performance status. Patients with cerebral tumors also require intensive care either before or after effective action. The controversy of economic and ethical issues still places aggressive action in intensive care on oncology patients. It is necessary to identify and know the characteristics of tumor patients that are useful in intensive management. AIM: The purpose of this study was to determine the demographic characteristics, length of stay, complications, and mortality rates of cerebral tumor patients undergoing intensive care at Sanglah Hospital Denpasar, the period January–December 2017. METHODS: This study is a cross-sectional descriptive where all sample data collection is secondarily based on existing medical records. The sample population in this study were cerebral tumor patients treated in the intensive care ward Sanglah period January–December 2017 who met the inclusion criteria. RESULTS: In the study, it found that 54 patients with the highest number of cerebral tumors treated in the intense sex with women (64.85%) and middle-aged adults (41–60 years) were 31 patients (57.4%). Most diagnoses of cerebral tumors were 39 non-glioma tumors (72.2%) followed by glioma tumors (20.4%) and tumor metastases (7.4%). Non-glioma tumors noted were meningiomas of around 48.1%, followed by glioblastoma multiforme tumors of 9.3%, tumors at the cerebellopontine angle and tumor metastases of 7.4%, respectively. All patients were treated intensively after receiving surgical therapy with a Karnofsky 50 score of about 29 patients (53.7%). All patients came out alive, and there were no recorded complications during treatment with the maximum length of stay of patients in the intensive care unit for up to 3 days by 45 patients (83.3%). CONCLUSION: The most brain tumor cases are meningioma, which occurred in women, middle-aged adults with no mortality and complications within 3 days during treatment intensive care.

MICRORNA IN MONITORING OF THE EVOLUTION OF GLIAL CEREBRAL TUMORS

Glial cerebral tumors (GCT) are primary tumors of the central nervous system that develop from glial tissue. Despite the use of combination treatment, the overall median survival rate in patients with glioblastoma, the most malignant form of HCC, is low. MicroRNA is a large class of endogenous small RNA molecules that inhibit mRNA translation of target genes involved in the evolution of GCT. It was shown that miRNA-21 has antiapoptotic and invasive functions by means of silencing of the PTEN tumor suppressor. MicroRNA-128 can activate a number of genes that are responsible for the mechanisms of suppression of tumor growth. MicroRNA-342, modulating PAK4 gene expression, is involved in the control of tumor cell proliferation, invasion and apoptosis.The aim of the work was to study the feasibility of using the assessment of miRNA-21, -128 and -342 expressions in the blood plasma and saliva of patients to monitor GCT progression or stabilization during combined modality treatment.Material and Methods. The main group consisted of 56 patients with GCTs. (34 men and 22 women), aged 25 to 72 years (average age 48.5 years) GCTs. The control group consisted of 50 people (45 volunteers and 5 neurosurgical patients with extracerebral meningiomas). The study of miRNA-21, -128, and -342 expressions was carried out according to the semiquantitative StemLoopRealTime protocol, using small U6 RNA as a reference gene. Data was processed using the STATISTICA for Windows computer system.Results. In 70 % of patients with disease progression assessed by magnetic resonance imaging, without progression in cerebral and focal neurological signs, the expression level of miRNA21 exceeded the control values both in blood plasma and saliva, and the expression levels of miRNA-128 and -342 were significantly reduced. In patients with GCT stabilization, the expression levels of miRNA-21, -128, and -342 did not go beyond the reference values. The diagnostic significance of miRNA-128, -342 for GCT was 69 %; therefore these miRNAs can be used in a clinical setting. Thus, the increased expression of miRNA-21 and decreased expressions of miRNA-128 and -342 in both blood plasma and saliva indicate cerebral glioma progression.